JP2018150240A - Bone formation promoter and food / beverage product composition using the same - Google Patents

Abstract

An object of the present invention is to provide an osteogenesis-promoting agent that has no side effects and is useful for the prevention and treatment of bone-related diseases such as osteoporosis. [Means for Solving Problem] An osteogenesis-promoting agent containing at least one of acai extract and Actinidia polymorpha extract as an active ingredient. [Selection figure] None

Description

  The present invention relates to an osteogenesis promoter and a food or drink composition using the same.

  In recent years, the life expectancy of mankind has been increasing due to advances in medicine and improvements in living standards. As the elderly population has increased, the number of bone-related diseases such as fractures, osteoporosis, rheumatoid arthritis, and periodontal disease has been increasing. In the bone tissue, osteoclasts that absorb old bones and osteoblasts that form new bones work together to maintain a healthy state. Due to factors such as aging and decreased ovarian function, the balance between bone resorption and bone formation is lost, resulting in a decrease in bone mass (bone density) and various bone-related diseases. As such bone-related diseases, fractures, osteoporosis, osteomalacia, osteopenia, bone defects, Paget's disease of bone, periodontal disease, rheumatoid arthritis, osteoarthritis and the like are known.

In particular, elderly people not only have difficulty in daily activities due to bone-related diseases, but also have the risk of becoming confined or bedridden. Therefore, prevention and treatment of bone-related diseases are important in today's aging society.
Currently, calcium, active vitamin D3, estrogen, calcitonin, ipriflavone, vitamin K2, and bisphosphonate-related compounds are used as therapeutic agents for bone-related diseases (see, for example, Patent Documents 1 and 2).

JP 2010-1000064 A Japanese Patent Laid-Open No. 2006-74964

However, the use of these drugs causes a high medical cost to the patient, and since it is administered only after diagnosis of a bone-related disease, the bone-related disease cannot be prevented.
In addition, none of the therapeutic agents can satisfy the therapeutic effect. As for calcitonin, there are problems that drug resistance is likely to appear and oral administration is impossible. The active vitamin D3 has a problem that a sufficient effect cannot be obtained and a problem that hypercalcemia tends to occur. Calcium drugs have problems such as requiring a very large amount of intake. Estrogen preparations are no exception in terms of the occurrence of side effects. During long-term administration over 6 months, side effects such as flushing of the face, breast pain, and genital bleeding from the uterus and vagina frequently occur. is there. In addition, estrogen preparations and bisphosphonates have an action to inhibit bone resorption, but do not directly promote bone formation by osteoblasts.

  The present invention has been made in view of the above circumstances, and an object of the present invention is to provide an osteogenesis promoter that has no side effects and is useful for the prevention and treatment of bone-related diseases.

As a result of intensive studies on the above problems, the present inventor has found that the above problems can be solved by an acai extract or a matababi extract, and has completed the present invention.
That is, the present inventor provides the following [1] to [5].
[1] An osteogenesis promoter containing as an active ingredient at least one of an acai extract or a matababi extract.
[2] A preventive or ameliorating agent for osteoporosis comprising at least one of an acai extract and a matababi extract as an active ingredient.
[3] The agent according to [1] or [2] above, wherein the acai extract is at least one of an extract of a fruit part and an extract of a seed part.
[4] A food / beverage composition for promoting bone formation comprising at least one of an acai extract or a matabi extract as an active ingredient.
[5] A food and beverage composition for preventing or improving osteoporosis, comprising at least one of an acai extract or a matababi extract as an active ingredient.

  According to the present invention, it is possible to provide an osteogenesis promoter that has no side effects and is useful for the prevention and treatment of bone-related diseases.

FIG. 1 is a bar graph showing the alkaline phosphatase activity of periodontal ligament cells using an acai extract. FIG. 2 is a bar graph showing the alkaline phosphatase activity of mesenchymal stem cells using an acai extract. FIG. 3 is a bar graph showing the alkaline phosphatase activity of periodontal ligament cells using the matababi extract. FIG. 4 is a bar graph showing alkaline phosphatase activity of mesenchymal stem cells using a matababi extract. FIG. 5 is a photograph showing the amount of calcium deposition.

  Hereinafter, the present invention will be described in detail with reference to preferred embodiments thereof.

[1. Bone formation promoter]
The osteogenesis promoter of the present invention contains at least one of acai extract and matatabi extract as an active ingredient.
In order to prevent bone-related diseases such as osteoporosis, it is well known that a large amount of calcium is consumed to increase bone mass (bone density). However, even if the amount of bone is greater than the average value, there are not a few people who suffer from a thigh fracture or the like, and it is claimed that an increase in the amount of bone alone is insufficient for preventing bone-related diseases. For the prevention of bone-related diseases, in addition to bone mass, the characteristics defined by bone material characteristics and structural characteristics (fine structure: porous cortical bone, trabecular structure of cancellous bone) are also important. It has become clear that.

Examples of bone material properties include bone resorption by osteoclasts and bone remodeling of bone formation by osteoblasts. The bone formation-promoting agent of the present invention is an invention that utilizes the bone formation-promoting action by osteoblasts among bone remodeling, which is a material property of bone.
Osteoblasts have high alkaline phosphatase activity, produce many bone matrix proteins such as type I collagen, and play a central role in bone formation. Osteoblasts responsible for bone formation in whole body bones and alveolar bone are thought to be supplied from mesenchymal stem cells and periodontal ligament cells.

Alkaline phosphatase is an important protein in the bone formation process, and not only decomposes mineralization inhibitors such as pyrophosphate but also contributes to an increase in local phosphate concentration necessary for hydroxyapatite crystal formation.
Therefore, the activity of promoting bone formation can be evaluated by inducing differentiation of mesenchymal stem cells and periodontal ligament cells into osteoblasts and examining the activity of alkaline phosphatase and the amount of calcium deposition.

The activity of alkaline phosphatase can be evaluated by a colorimetric method, an enzyme immunoassay (EIA method) or a chemiluminescent enzyme immunoassay (CLEIA method).
The colorimetric method is a method in which a measurement substance or a reaction product is changed to a color developing substance, and the degree of color development is colorimetrically determined by absorbance using visible light having an appropriate wavelength.
The EIA method is a method for obtaining an antigen or antibody amount of alkaline phosphatase by binding an enzyme such as horseradish peroxidase to an antigen or antibody and knowing the degree of the antigen-antibody reaction using the enzyme activity as a marker.
The CLEIA method is a measurement method in which alkaline phosphatase is labeled and chemiluminescence of a product produced by a substrate or an enzyme reaction is detected, or the product is introduced into a chemiluminescence reaction to detect luminescence. Examples of the luminescence detection system include a luminol / hydrogen peroxide system and a dioxetane derivative system.

  The activity of alkaline phosphatase can also be evaluated using a commercially available product. Examples of such commercially available products include an alkaline phosphatase measurement kit (trade name “Lab Assay ALP”, manufactured by Wako Pure Chemical Industries, Ltd.).

[2. Osteoporosis preventive or ameliorating agent]
The osteoporosis preventive or ameliorating agent of the present invention comprises at least one of acai extract and matatabi extract as an active ingredient. As described above, the acai extract and the matababi extract have an action of promoting bone formation by osteoblasts among bone remodeling, which is a material property of bone. Therefore, osteoporosis is prevented or improved not by increasing bone mass but by promoting bone formation, that is, improving bone quality. The preventive or ameliorating agent for osteoporosis of the present invention was invented based on the novel finding that acai extract and matababi extract improve bone quality by promoting bone formation, not by increasing bone mass by conventional calcium. Is.

(Acai extract)
Acai (Euterpe oleracea) is a hermaphroditic palmaceous plant that inhabits northern South America (Amazon). The fruit looks like blueberries and is edible. The pulp contains polyphenols and anthocyanins such as cyanidin-3-glycoside, pelargonidin-3-glycoside, ferulic acid, (−)-epicatechin, gallic acid and ellagic acid. In addition, the seed contains 63 to 81% of fibers such as cellulose and hemicellulose, and protocatechuic acid.

The component parts of acai that can be used as an extraction raw material include, for example, a flower part, a cocoon part, a fruit part, a fruit skin part, a seed part, a seed coat part, a stem part, a leaf part, a branch part, a branch part, a trunk part, and a bark part. , Root part, rhizome part, root bark part. Moreover, the combination part of the different part may be sufficient as the structure part of the acai which can be used as an extraction raw material. Especially, it is preferable that an acai extract is at least any one of the extract of a fruit part, and the extract of a seed part.
In addition, when using the fruit part of an acai as an extraction raw material, the fruit itself may be used and the puree of a fruit may be used.

  When the acai fruit itself is used as an extraction raw material, for example, after drying, it can be subjected to solvent extraction as it is or after being pulverized using a crusher. Drying may be performed, for example, in the sun or using a commonly used dryer. The acai fruit may be used as an extraction raw material after pretreatment such as defatting with a nonpolar solvent such as hexane or benzene. By performing pretreatment such as degreasing, the extraction treatment of acai fruit with a polar solvent can be performed efficiently.

  The method for obtaining the extract from acai is not particularly limited, and can be performed by utilizing a method generally used for plant extraction. Examples include polar solvent extraction and supercritical extraction. Only one of these extraction operations may be performed, or both of them may be performed. In addition, each extraction operation may be performed only once, or may be performed twice or more. The acai fruit extract includes an acai fruit extract, a diluted or concentrated liquid of the extract, a dried product of the extract, and a crude product or a purified product thereof.

  When extracting by polar solvent extraction, there is no restriction | limiting in particular as a solvent used for extraction, According to the objective, it can select suitably. Examples of the polar solvent include water, a hydrophilic organic solvent, or a mixed solvent thereof.

  There is no restriction | limiting in particular as water which can be used as an extraction solvent, According to the objective, it can select suitably. For example, pure water, tap water, distilled water, mineral water, alkaline ionized water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, as well as those subjected to various treatments are included. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. The water that can be used as the extraction solvent includes purified water, hot water, ion exchange water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.

There is no restriction | limiting in particular as a hydrophilic organic solvent, According to the objective, it can select suitably. For example, lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; carbon numbers such as 1,3-butylene glycol, ethylene glycol, propylene glycol and glycerin 2 to 5 polyhydric alcohols; acetic acid and ethyl acetate.
From the viewpoint of efficiently extracting active ingredients, the solvent used for extraction is preferably water, methanol, or ethanol.

  When water is used as the extraction solvent, the extraction temperature is 20 to 100 ° C, preferably about 40 to 70 ° C. This is because if the extraction temperature is too low, it is difficult to extract the active ingredient.

  When a mixed solvent of water and a hydrophilic organic solvent is used as the extraction solvent, the blending amount can be described as follows. When using lower alcohol as a hydrophilic organic solvent, it is 1 mass part-90 mass parts with respect to 10 mass parts of water. When using a lower aliphatic ketone, it is 1-40 mass parts with respect to 10 mass parts of water. When using a polyhydric alcohol, it is 1 mass part-90 mass parts with respect to 10 mass parts of water. The extraction temperature is 0 to 95 ° C, preferably about 20 to 80 ° C. In addition, when extracting with a mixed solvent, in order to improve the content rate of an active ingredient, it is preferable to carry out repeatedly at various density | concentrations.

  Moreover, when extracting by polar solvent extraction, the extraction method is not specifically limited. For example, any method such as continuous extraction, immersion extraction, or countercurrent extraction can be employed. Any apparatus can be used from room temperature to heating under reflux. When extraction is performed by the above-described method, only one of these extraction methods may be performed or a combination thereof may be performed. Moreover, these extractions may be performed only once or may be performed twice or more.

  As a specific method, an extraction raw material (a puree excluding acai fruits or seeds) is put into a treatment tank filled with an extraction solvent, and an active ingredient is eluted while stirring. For example, when water or water-containing alcohol is used as the extraction solvent, the extraction is performed for about 1 minute to 150 hours using a polar solvent of about 5 to 100 times (mass ratio) the extraction raw material. The active ingredient is eluted in the solvent, and then filtered to remove the extraction residue to obtain an extract.

  Acai extract obtained by extraction is diluted, concentrated, dried or purified according to a conventional method in order to obtain a diluted or concentrated solution, a dried extract, or a crude or purified product thereof. You may give it. The obtained acai extract can be used as it is, but a concentrated solution or a dried product thereof is easier to use. In obtaining the dried extract, a conventional method can be used, and carriers such as dextrin and cyclodextrin may be added to improve hygroscopicity. In addition, it is possible to carry out purification for the purpose of decolorization, deodorization and the like within a range not causing a decrease in the physiological activity of the acai extract, but there is no practical problem even if it is not purified. Specifically, purification can be performed by activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, liquid-liquid countercurrent distribution, membrane separation, and the like.

When performing extraction by supercritical extraction, the supercritical fluid is not particularly limited. For example, carbon dioxide and nitrogen are mentioned. Among these, carbon dioxide is preferable from the viewpoint of more easily extracting the active ingredient.
Note that only one type of supercritical fluid may be used, or two or more types may be used in combination.

The extraction method may be performed by a known method. Thereafter, the acai extract can be obtained by subjecting the extract to treatments such as dilution, concentration, drying and purification according to a conventional method.
In addition, you may use a commercial item as an acai extract. As a commercial item, the product name "Acai powder" by Prime Trading Co., Ltd. is mentioned, for example.

  The content of the acai extract in the osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention is appropriately selected depending on the dosage form, administration form, and administration target. For example, in the case of oral ingestion, 0.01 to 10% by mass is preferable in terms of solid content in the composition or food, and 0.1 to 10% by mass is more preferable. The intake per adult is preferably 100 mg / day or more, more preferably 100 to 500 mg / day.

  Acai is known to contain a lot of calcium. As described above, an increase in bone mass due to an increase in calcium is not sufficient for prevention and improvement of bone-related diseases such as osteoporosis. In the present invention, the acai extract has an action of promoting bone formation by osteoblasts among bone remodeling, which is one of the material properties of bone, so that bone quality can be improved and bone-related diseases can be improved. Prevention and improvement can be achieved. In addition, since the acai extract also contains a large amount of calcium, an increase in bone mass is also expected. Therefore, since the bone strength by both the performance of the bone quality and the bone mass can be improved, the acai extract is preferable for the prevention and improvement of osteoporosis among bone related diseases.

(Matatabi extract)
Matabi (Actinidia polygamama) is a hermaphroditic deciduous vine plant belonging to the genus Matabiidae that grows from Hokkaido to Kyushu, the Korean Peninsula, etc., and is easily available from these regions. The fruit of Matabi is a berry and is oval or oval. Its tip becomes thin in the shape of a beak, is 2 to 2.5 cm in length and about 1 cm in diameter, ripens yellow, and has a pungent taste when eaten. The fruit of matababi is eaten raw or salted. In addition, there is a case where a matababi fruit fly parasitizes on the fruit of matatabi, and there is a case where a bumpy insect bump is formed on the surface. ). Wooden tempura has a warming action and an analgesic action, and has been used for medicinal liquor. The fruit contains matatabic acid, cutinidine, matatabilactone and the like.

Examples of the constituent parts of matabi can be used as an extraction raw material include, for example, a flower part, a cocoon part, a fruit part, a fruit skin part, a seed part, a seed coat part, a stem part, a leaf part, a branch part, a branch leaf part, a trunk part, a bark part , Root part, rhizome part, root bark part. Moreover, the combination part of a different part may be sufficient as the structural part of the matabi which can be used as an extraction raw material. Especially, it is preferable that a matababi extract is a fruit part.
In addition, when using the fruit part of a matabi as an extraction raw material, the fruit itself may be used and the thing which became the state of the insect hump may be used.

  In the case of using a matabi fruit as an extraction raw material, for example, after drying, it can be subjected to solvent extraction as it is or after being pulverized using a crusher. Drying may be performed, for example, in the sun or using a commonly used dryer. In addition, you may use the fruit of Matatabi as an extraction raw material, after giving pretreatments, such as degreasing, with nonpolar solvents, such as hexane and benzene. By performing a pretreatment such as degreasing, the extraction process of the fruit of the matababi with a polar solvent can be efficiently performed.

  The method for obtaining the extract from the matababi is not particularly limited, and can be performed by utilizing a method generally used for plant extraction. Examples include polar solvent extraction and supercritical extraction. Only one of these extraction operations may be performed, or both of them may be performed. In addition, each extraction operation may be performed only once, or may be performed twice or more. In addition, the extract of a matababi fruit includes an extract of a matababi fruit, a diluted or concentrated liquid of the extract, a dried product of the extract, or a crudely purified product or a purified product thereof.

  When extracting by polar solvent extraction, there is no restriction | limiting in particular as a solvent used for extraction, According to the objective, it can select suitably. Examples of the polar solvent include water, a hydrophilic organic solvent, or a mixed solvent thereof.

  There is no restriction | limiting in particular as water which can be used as an extraction solvent, According to the objective, it can select suitably. For example, pure water, tap water, distilled water, mineral water, alkaline ionized water, well water, mineral spring water, mineral water, hot spring water, spring water, fresh water, and the like, as well as those subjected to various treatments are included. Examples of the treatment applied to water include purification, heating, sterilization, filtration, ion exchange, adjustment of osmotic pressure, buffering, and the like. The water that can be used as the extraction solvent includes purified water, hot water, ion exchange water, physiological saline, phosphate buffer, phosphate buffered saline, and the like.

There is no restriction | limiting in particular as a hydrophilic organic solvent, According to the objective, it can select suitably. For example, lower alcohols having 1 to 5 carbon atoms such as methanol, ethanol, propyl alcohol and isopropyl alcohol; lower aliphatic ketones such as acetone and methyl ethyl ketone; carbon numbers such as 1,3-butylene glycol, ethylene glycol, propylene glycol and glycerin 2 to 5 polyhydric alcohols; acetic acid and ethyl acetate.
From the viewpoint of efficiently extracting active ingredients, the solvent used for extraction is preferably water, methanol, or ethanol.

  When water is used as the extraction solvent, the extraction temperature is 20 to 100 ° C, preferably about 40 to 70 ° C. This is because if the extraction temperature is too low, it is difficult to extract the active ingredient.

  When a mixed solvent of water and a hydrophilic organic solvent is used as the extraction solvent, the blending amount can be described as follows. When using lower alcohol as a hydrophilic organic solvent, it is 1 mass part-90 mass parts with respect to 10 mass parts of water. When using a lower aliphatic ketone, it is 1-40 mass parts with respect to 10 mass parts of water. When using a polyhydric alcohol, it is 1 mass part-90 mass parts with respect to 10 mass parts of water. The extraction temperature is 0 to 95 ° C, preferably about 20 to 80 ° C. In addition, when extracting with a mixed solvent, in order to improve the content rate of an active ingredient, it is preferable to carry out repeatedly at various density | concentrations.

  Moreover, when extracting by polar solvent extraction, the extraction method is not specifically limited. For example, any method such as continuous extraction, immersion extraction, or countercurrent extraction can be employed. Any apparatus can be used from room temperature to heating under reflux. When extraction is performed by the above-described method, only one of these extraction methods may be performed or a combination thereof may be performed. Moreover, these extractions may be performed only once or may be performed twice or more.

  As a specific method, an extraction raw material (matababi fruit) is put into a treatment tank filled with an extraction solvent, and an active ingredient is eluted while stirring. For example, when water or water-containing alcohol is used as the extraction solvent, the extraction is performed for about 1 minute to 150 hours using a polar solvent of about 5 to 100 times (mass ratio) the extraction raw material. The active ingredient is eluted in the solvent, and then filtered to remove the extraction residue to obtain an extract. Thereafter, the extract can be obtained by subjecting the extract to dilution, concentration, drying, purification and the like according to a conventional method.

  In order to obtain a dilute solution or concentrated solution, a dried product of the extract, or a crudely purified product or purified product thereof, the extract of matatabi obtained by extraction is subjected to treatments such as dilution, concentration, drying and purification according to a conventional method. You may give it. In addition, although the extract of matatabi obtained can be used as it is, a concentrated solution or a dried product thereof is easier to use. In obtaining the dried extract, a conventional method can be used, and carriers such as dextrin and cyclodextrin may be added to improve hygroscopicity. In addition, it is possible to carry out purification for the purpose of decolorization, deodorization and the like within a range that does not cause a decrease in the physiological activity of the extract of matababi, but there is no practical problem even if it is not purified. Specifically, purification can be performed by activated carbon treatment, adsorption resin treatment, ion exchange resin treatment, liquid-liquid countercurrent distribution, membrane separation, and the like.

When performing extraction by supercritical extraction, the supercritical fluid is not particularly limited. For example, carbon dioxide and nitrogen are mentioned. Among these, carbon dioxide is preferable from the viewpoint of more easily extracting the active ingredient.
Note that only one type of supercritical fluid may be used, or two or more types may be used in combination.

The extraction method may be performed by a known method. Thereafter, the extract can be subjected to treatments such as dilution, concentration, drying, and purification according to a conventional method to obtain a matababi extract.
In addition, a commercial item may be used for a matababi extract. As a commercial item, Maruzen Pharmaceutical Co., Ltd. make and a brand name "Matabi extract BG30" are mentioned, for example.

  The content of the matababi extract in the osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention is appropriately selected depending on the dosage form, administration form, and administration target. For example, in the case of oral ingestion, 0.001 to 50 mass% is preferable and 0.1 to 20 mass% is more preferable in terms of solid content in the composition or food and drink. The intake amount per adult is preferably 100 mg / day or more, more preferably 500 to 1000 mg / day.

(Optional component)
The osteogenesis promoter of the present invention or the preventive or ameliorating agent for osteoporosis of the present invention may contain other optional components as long as the effects of the present invention are not inhibited. For example, excipients, disintegrants, binders, lubricants, coating agents, colorants, color formers, flavoring agents, flavoring agents, antioxidants, preservatives, flavoring agents, sour agents, sweeteners, strengthening And pharmacologically acceptable additives such as a vitamin, a vitamin, a swelling agent, a thickener, and a surfactant. Of these, the dosage form of the final product (for example, food / drinks, pharmaceuticals, quasi-drugs, nutritional supplements (supplements), etc.) without damaging various properties required for the formulation (for example, formulation stability) Depending on the type, one or more additives may be selected.

(Dosage form)
The osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention is not particularly limited as long as at least one of an acai extract and a matababi extract can be used as an active ingredient.
Examples of dosage forms for oral administration include liquid (liquid), syrup (syrup), solid (tablet), capsule (capsule), powder (granule, fine granule), soft capsule ( Soft capsules), semi-liquid, cream, and paste.
Examples of dosage forms for parenteral administration include liquids (injections, nasal drops) and mists (sprays, inhalants).
These preparations can be prepared by mixing the osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention with a pharmacologically acceptable medium.

  The dosage form of the osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention is not particularly limited, and may be either oral administration or parenteral administration. However, oral administration is preferred because it is less invasive. Examples of oral administration include oral administration and sublingual administration. Examples of parenteral administration include intravenous administration, intramuscular administration, subcutaneous administration, transdermal administration, nasal administration, and pulmonary administration.

  The administration timing of the osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention is not particularly limited. It can be administered before meals, between meals, after meals, and before going to bed. In particular, since the osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention has no side effects, it may be administered three times a day after meals or twice a day in the morning or after dinner. May be.

  The subject who takes the osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention is not particularly limited. Examples of the ingestion target include a person in a growth period from 12 to 18 years old, a person diagnosed with osteoporosis, and an elderly person over 65 years old. Moreover, even if it is a subject without a special problem, an athlete, a manual worker, etc. can take it on a daily basis for the purpose of improving bone quality.

  The osteogenesis promoter of the present invention or the osteoporosis prevention or amelioration agent of the present invention may be used as an additive for food and drink, a pharmaceutical additive, or an quasi-drug additive. Thereby, the effect which accelerates | stimulates bone formation can be provided to food-drinks, a pharmaceutical, and a quasi-drug.

[3. Food / beverage composition for promoting bone formation, food / beverage composition for preventing or improving osteoporosis]
The food / beverage composition for promoting bone formation of the present invention or the food / beverage composition for preventing or improving osteoporosis of the present invention comprises at least one of an acai extract and a matababi extract as an active ingredient.
The bone formation promoting food / beverage composition of the present invention or the osteoporosis prevention / ameliorating food / beverage composition of the present invention is used as a food / beverage product that is expected to have the above-described osteogenesis promoting effect and the effects associated therewith. be able to. Examples of such foods and beverages include health foods, functional foods, dietary supplements (supplements), foods for specified health use, medical foods, foods for the sick, foods for infants, foods for nursing care, foods for the elderly Is mentioned.

  There is no restriction | limiting in particular in the form of food / beverage products, For example, a drink (a soft drink, a carbonated drink, a nutrition drink, a powdered drink, a fruit drink, a milk drink, a jelly drink etc.), confectionery (a rice cake, a cookie, chocolate, cake, gum, Candy, tablets, gummi, buns, snacks, biscuits, sheep mushrooms, pudding, jelly, ice cream, sorbet, shaved ice, etc.), processed fishery products (kamaboko, chikuwa, hanpen, etc.), livestock products (hamburger, ham, sausage, winner) , Cheese, butter, yogurt, fresh cream, margarine, fermented milk, etc.), soups (powder soup, liquid soup, etc.), staple foods (rice, noodles (dried noodles, raw noodles), bread, cereals, etc.), seasonings (Mayonnaise, shortening, dressing, sauce, sauce, soy sauce, etc.), retort pouch food (curry, stew, Child bowl, porridge, porridge, Chinese bowl and bowl,, tendon, Unadon, hashed rice, Oden, Mabodofu, beef bowl, meat sauce, egg soup, omelet, dumplings, Shumai, hamburgers, meat balls, etc.). Also includes pharmaceuticals such as tablets, capsules, drinks, troches, and granules, and quasi drugs.

The food / beverage composition for promoting bone formation of the present invention or the food / beverage composition for preventing or improving osteoporosis of the present invention may contain other components as long as the effects of the present invention are not impaired. There is no restriction | limiting in particular as another component, According to the objective, it can select suitably. For example, auxiliary raw materials or additives that are usually used in producing foods and drinks can be mentioned.
There is no restriction | limiting in particular as an auxiliary | assistant raw material or an additive, According to the objective, it can select suitably. For example, fructose, granulated sugar, sucrose, sugar, glucose, maltose, sorbitol, stevioside, rubusoside, corn syrup, lactose, starch syrup, reduced starch syrup, corn starch, starch degradation product, citric acid, tartaric acid, malic acid, succinic acid, lactic acid , L-ascorbic acid, dl-α-tocopherol, sodium erythorbate, glycerin, propylene glycol, glycerin fatty acid ester, polyglycerin fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, polyvinyl pyrrolidone, gum arabic, carrageenan, casein, gelatin , Pectin, agar, vitamin B, nicotinamide, calcium pantothenate, amino acids, calcium salts, crystalline cellulose, gum base, flavor, pigment, fragrance, preservative, fruit juice It is below.

  Hereinafter, the present invention will be described in detail with reference to examples. The following examples are for explaining the present invention preferably and are not intended to limit the present invention. In addition, unless otherwise indicated, the measuring methods, such as a physical-property value, are the measuring methods described above.

Example 1
Human periodontal ligament cells were cultured in 10% FBS, α-MEM culture medium at 37 ° C., 5% CO ₂ -95% Air until confluent. The cells were collected by trypsin-EDTA treatment, and 1 × 10 ⁵ cells were seeded in a 24-well plate using the culture solution. After culturing for 18 hours and allowing the cells to adhere to the plate, no addition (control) to the calcification promotion medium (10 mmol / Lβ glycerophosphate, 50 μg / mL L-ascorbic acid in the culture medium), 1 ppm, 10 ppm, 100 ppm acai The extract was added and cultured. After 12 days, the culture supernatant was removed, the cells were washed with phosphate buffer pH 7.4, and then 500 μL of a solution (50 mM Tris-HCl (Wako Pure Chemicals), 0.1% Triton X (Roche), 0.9 % NaCl (Wako Pure Chemical Industries, Ltd., pH 7.6), the cells were crushed and the protein was extracted.

The protein extract obtained by centrifuging this disrupted solution at 12000 rpm, 4 ° C. for 15 minutes was transferred to a 96-well multiplate (IWAKI), and the activity was measured using an alkaline phosphatase measurement kit (Lab Assay ALP, Wako Pure Chemical Industries). The absorbance at 405 nm of the reaction solution of the measurement kit was measured with a microplate reader. A value obtained by dividing the obtained OD value by the amount of DNA was defined as an activity value. The rate of increase in alkaline phosphatase activity due to the addition of the acai extract when the control activity was 100% was determined. The result was analyzed by student't test (vs control), and p <0.05 was considered significant.
The results are shown in FIG.

  In addition, 100 ppm of acai extract was added to the calcification promoting medium, cultured for 21 days, the culture supernatant was removed, and the cells were washed with phosphate buffer pH 7.4, and then 500 μL of the cells were washed. Calcium was stained with a 1% Alizarin red solution (manufactured by Wako Pure Chemical Industries, Ltd.), and the amount of calcium deposition was examined. A photograph showing the amount of calcium deposition is shown in FIG. 5 together with the control.

(Example 2)
Alkaline phosphatase activity increase rate was determined in the same manner as in Example 1 except that human mesenchymal stem cells were used instead of human periodontal ligament cells. The results are shown in FIG.

As can be seen from FIG. 1 and FIG. 2, an increase in alkaline phosphatase activity was observed by adding an acai extract in any of human periodontal ligament cells and human mesenchymal stem cells. . The effect was particularly remarkable at 10 ppm or more (p <0.05).
In Examples 1 and 2, Prime Trade Company, trade name “Acai Powder” was used as the Acai extract.

(Example 3)
Alkaline phosphatase activity increase rate was determined in the same manner as in Example 1 except that the matahabi extract was used instead of the acai extract. The results are shown in FIG. Moreover, like Example 1, the photograph which shows the amount of calcium deposits at the time of adding 100 ppm matatabi extract is shown with a control in FIG.

(Example 4)
Alkaline phosphatase activity increase rate was determined in the same manner as in Example 2 except that Matabi extract was used instead of Acai extract. The results are shown in FIG.

As can be seen from FIG. 3 and FIG. 4, an increase in alkaline phosphatase activity was observed by adding a matababi extract, regardless of whether human periodontal ligament cells or human mesenchymal stem cells were used. . The effect was particularly remarkable at 10 ppm or more (p <0.05).
In Examples 3 and 4, Marutabi Pharmaceutical Co., Ltd., trade name “Matatabi Extract BG30” was used as the matatabi extract.

  As can be seen from FIG. 5, it can be seen that the amount of calcium deposition is increased in both cases of the acai extract and the matatabi extract. Therefore, it is recognized that good calcium deposition occurs due to the activity of alkaline phosphatase, and excellent bone formation is achieved.

Formulation examples using Acai extract (Prime Trading Co., Ltd., trade name “Acai Powder”) and / or Matatabi extract (Maruzen Pharmaceutical Co., Ltd., trade name “Matatabi Extract BG30”) are described below.
(Prescription Example 1: Tablet)
Lactose 54.0wt%
Crystalline cellulose 30.0wt%
Starch degradation product 10.0wt%
Glycerin fatty acid ester 5.0wt%
Acai extract 1.0wt%
Total 100.0wt%

(Prescription Example 2: Tablet)
Lactose 53.0wt%
Crystalline cellulose 30.0wt%
Starch degradation product 10.0wt%
Glycerin fatty acid ester 5.0wt%
Matabi extract 2.0wt%
Total 100.0wt%

(Prescription Example 3: Tablet)
Lactose 53.0wt%
Crystalline cellulose 30.0wt%
Starch degradation product 10.0wt%
Glycerin fatty acid ester 5.0wt%
Acai extract 1.0wt%
Matatabi extract 1.0wt%
Total 100.0wt%

(Prescription Example 4: Oral Granules (Pharmaceuticals))
Lactose 30.0wt%
Corn starch 59.0wt%
Crystalline cellulose 8.0wt%
Polyvinylpyrrolidone 1.0wt%
Acai extract 2.0wt%
Total 100.0wt%

(Prescription Example 5: Oral Granules (Pharmaceuticals))
Lactose 30.0wt%
Cornstarch 60.0wt%
Crystalline cellulose 8.0wt%
Polyvinylpyrrolidone 1.0wt%
Matatabi extract 1.0wt%
Total 100.0wt%

(Prescription Example 6: Oral Granules (Pharmaceuticals))
Lactose 30.0wt%
Corn starch 59.0wt%
Crystalline cellulose 8.0wt%
Polyvinylpyrrolidone 1.0wt%
Acai extract 1.0wt%
Matatabi extract 1.0wt%
Total 100.0wt%

(Formulation example 7: chewing gum)
53.0wt% sugar
Gum base 20.0wt%
Glucose 10.0wt%
Minamata 16.0wt%
Flavor 0.5wt%
Acai extract 0.5wt%
Total 100.0wt%

(Prescription Example 8: Chewing gum)
52.5 wt% sugar
Gum base 20.0wt%
Glucose 10.0wt%
Minamata 16.0wt%
Flavor 0.5wt%
Matatabi extract 1.0wt%
Total 100.0wt%

(Formulation example 9: chewing gum)
52.5 wt% sugar
Gum base 20.0wt%
Glucose 10.0wt%
Minamata 16.0wt%
Flavor 0.5wt%
Acai extract 0.5wt%
Matatabi extract 0.5wt%
Total 100.0wt%

(Prescription Example 10: Gummy)
Reduced water tank 40.0wt%
Granulated sugar 20.0wt%
Glucose 20.0 wt%
Gelatin 4.7wt%
Water 9.18wt%
Fruit juice 4.0wt%
Flavor 0.6wt%
Dye 0.02wt%
Acai extract 1.5wt%
Total 100.0wt%

(Prescription Example 11: Gummy)
Reduced water tank 40.0wt%
Granulated sugar 20.0wt%
Glucose 20.0 wt%
Gelatin 4.7wt%
Water 9.68wt%
Fruit juice 4.0wt%
Flavor 0.6wt%
Dye 0.02wt%
Matatabi extract 1.0wt%
Total 100.0wt%

(Prescription Example 12: Gummy)
Reduced water tank 40.0wt%
Granulated sugar 20.0wt%
Glucose 19.0wt%
Gelatin 4.7wt%
Water 9.18wt%
Fruit juice 4.0wt%
Flavor 0.6wt%
Dye 0.02wt%
Acai extract 1.5wt%
Matatabi extract 1.0wt%
Total 100.0wt%

Claims (5)

  An osteogenesis promoter comprising at least one of an acai extract or a matababi extract as an active ingredient.   A preventive or ameliorating agent for osteoporosis, comprising at least one of an acai extract and a matababi extract as an active ingredient.   The agent according to claim 1 or 2, wherein the acai extract is at least one of an extract of a fruit part and an extract of a seed part.   A food / beverage composition for promoting bone formation comprising at least one of an acai extract and a matababi extract as an active ingredient.   A food or beverage composition for prevention or improvement of osteoporosis, comprising at least one of an acai extract or a matababi extract as an active ingredient.